Evaluation of the efficacy, safety, and economy of nemonoxacin injection versus moxifloxacin injection in the treatment of community-acquired pneumonia
Abstract
Objective To evaluate the clinical efficacy, safety, and cost-effectiveness of nemonoxacin injection versus moxifloxacin injection in patients with community-acquired pneumonia (CAP), providing an evidence-based reference for clinical decision-making. Methods A retrospective cohort study was conducted, enrolling 196 patients hospitalized with CAP between January 2024 and March 2025. Based on the treatment received, patients were allocated to a nemonoxacin group (n = 103) or a moxifloxacin group (n = 93). Clinical efficacy, inflammatory markers before and after treatment, and safety outcomes were compared between the groups. A cost-minimization analysis was used for the economic evaluation. Results Baseline characteristics did not differ significantly between groups (P > 0.05). Clinical efficacy was 100.0% in the nemonoxacin group versus 97.8% in the moxifloxacin group (P = 0.135). Adverse reaction rates were 1.9% and 1.1% for nemonoxacin and moxifloxacin, respectively (P = 0.622). Inflammatory markers decreased significantly after treatment in both groups, but the intergroup difference post-treatment was not statistically significant (P > 0.05). The total hospitalization cost was significantly lower in the nemonoxacin group (¥6,726.31 ± 1,849.50) than in the moxifloxacin group (¥7,354.12 ± 2,477.16) (P = 0.044), indicating superior cost-effectiveness for nemonoxacin. Sensitivity analysis supported the robustness of the economic finding. Conclusion Nemonoxacin malate…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 196 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.